Atavistik Bio is using the cash to develop “allosteric” medicines it believes can offer precise impact on diseases like myelofibrosis and the blood condition HHT.Atavistik Bio has raised $160 million in its pursuit of new treatments for rare hematological disorders and cancers, the company said Thursday.The Series B round, which was originally announced in December […]
